Survival Strategies

Home/Tag: Survival Strategies

Informative Webcast Sheds Light on Mutational Analysis

Dr. Chris Corless In August, the LRG Webcast Series presented “Mutational Analysis of GISTs: How, When and Why.” Dr. Christopher Corless of Oregon Health and Science University (OHSU) presented the hour- long [...]

First GDOL Chicago hits a homerun!

Our first Chicago GIST Day of Learning (GDOL) was a huge success! Over 50 GISTers and their families gathered for a great day of learning, and sharing experiences. It was wonderful to get to meet so many new people and reconnect with old friends.

By |2019-09-20T12:33:07-04:00June 11th, 2013|GIST Education, Gleevec, News, Patient Support, Survival Strategies|

Mutational Testing & Survival: Where We Stand

Only six percent of GIST patients in the United States take advantage of testing that could be used to individualize their treatment according to a new article in the Annals of Oncology. Dr. Peter Pisters of MD Anderson Cancer Center in Houston, Texas and his colleagues reported results of the GIST reGISTry, a Novartis Pharmaceuticals-supported registry of 882 GIST patients in the United States.

By |2019-04-05T09:52:42-04:00June 1st, 2011|Mutational Testing, News, Survival Strategies|

PDGFRA Mutations: It’s time to consider mutational status for resistant GIST patients

January 6th, 2011 - By Jerry Call,  LRG Science CoordinatorThe first ever clinical trial specifically for the PDGFRA D842V mutation has been announced by Arog pharmaceuticals. The phase II trial is scheduled to open in [...]

It’s Time to Consider Mutational Status for Resistant GIST Patients: KIT exons 9 & 11

KIT exon 11 and exon 9 mutations represent the two most common types of mutations (wild-type GIST is technically not a type of mutation but a lack of mutations) found in GIST patients. About 60 to 65 percent of GIST patients have a KIT exon 11 mutation and about 10 to15 percent have a KIT exon 9 mutation.

By |2018-12-20T10:24:33-05:00February 1st, 2010|Mutational Testing, News, Survival Strategies|

Plasma level testing: what we know, what we don’t & what we hope to learn

This month, Novartis Pharmaceuticals (maker of Gleevec) launched a new website designed to help optimize the outcome of GIST patients taking Gleevec. Some of the featured content is about blood level testing for GIST. In addition, the website prominently links to the Avantix labs website ( for testing Gleevec blood levels in CML and GIST.

By |2019-04-08T08:52:11-04:00January 28th, 2009|News, Research, Survival Strategies|
Go to Top